Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 197

1.

Repurposing nitrocatechols: 5-Nitro-α-cyanocarboxamide derivatives of caffeic acid and caffeic acid phenethyl ester effectively inhibit aggregation of tau-derived hexapeptide AcPHF6.

Silva T, Mohamed T, Shakeri A, Rao PPN, Soares da Silva P, Remião F, Borges F.

Eur J Med Chem. 2019 Feb 4;167:146-152. doi: 10.1016/j.ejmech.2019.02.006. [Epub ahead of print]

PMID:
30771602
2.

Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors.

Pinheiro SD, Serrão MP, Silva T, Borges F, Soares-da-Silva P.

Eur J Pharmacol. 2019 Jan 24;847:53-60. doi: 10.1016/j.ejphar.2019.01.027. [Epub ahead of print]

PMID:
30685433
3.

Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: A pooled-analysis of data from two Phase 3 clinical trials and their open-label extensions.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P.

Eur J Neurol. 2019 Jan 25. doi: 10.1111/ene.13914. [Epub ahead of print]

PMID:
30681754
4.

Effects of zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failure.

Igreja B, Pires NM, Wright LC, Soares-da-Silva P.

Eur J Pharmacol. 2019 Jan 5;842:125-132. doi: 10.1016/j.ejphar.2018.10.030. Epub 2018 Oct 26.

PMID:
30401628
5.

Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures.

Costa R, Steinhoff B, Gama H, Ikedo F, Rocha JF, Soares-da-Silva P.

Drugs Aging. 2018 Dec;35(12):1109-1117. doi: 10.1007/s40266-018-0602-y.

6.

Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.

Kitajima T, Mizote S, Bonifácio MJ, Umemura T, Yoneda K, Moser P, Soares-da-Silva P, Tanaka M.

Neuropharmacology. 2018 Dec;143:282-288. doi: 10.1016/j.neuropharm.2018.10.001. Epub 2018 Oct 2.

7.

Discovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 10-2474) of Fatty Acid Amide Hydrolase.

Kiss LE, Beliaev A, Ferreira HS, Rosa CP, Bonifácio MJ, Loureiro AI, Pires NM, Palma PN, Soares-da-Silva P.

ChemMedChem. 2018 Oct 22;13(20):2177-2188. doi: 10.1002/cmdc.201800393. Epub 2018 Sep 11.

PMID:
30113139
8.

Effects of eslicarbazepine on slow inactivation processes of sodium channels in dentate gyrus granule cells.

Holtkamp D, Opitz T, Hebeisen S, Soares-da-Silva P, Beck H.

Epilepsia. 2018 Aug;59(8):1492-1506. doi: 10.1111/epi.14504. Epub 2018 Jun 28.

PMID:
29953587
9.

Polyamine Modulation of Anticonvulsant Drug Response: A Potential Mechanism Contributing to Pharmacoresistance in Chronic Epilepsy.

Beckonert NM, Opitz T, Pitsch J, Soares da Silva P, Beck H.

J Neurosci. 2018 Jun 13;38(24):5596-5605. doi: 10.1523/JNEUROSCI.0640-18.2018. Epub 2018 May 22.

10.

Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.

Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B, Soares-da-Silva P.

Neurology. 2018 May 22;90(21):e1849-e1857. doi: 10.1212/WNL.0000000000005557. Epub 2018 Apr 25.

PMID:
29695590
11.

Eslicarbazepine acetate exposure in pregnant women with epilepsy.

Costa R, Magalhães LM, Graça J, Vieira M, Gama H, Moreira J, Rocha JF, Soares-da-Silva P.

Seizure. 2018 May;58:72-74. doi: 10.1016/j.seizure.2018.04.007. Epub 2018 Apr 10. Review.

12.

Antihypertensive effect of etamicastat in dopamine D2 receptor-deficient mice.

Armando I, Asico LD, Wang X, Jones JE, Serrão MP, Cuevas S, Grandy DK, Soares-da-Silva P, Jose PA.

Hypertens Res. 2018 Jul;41(7):489-498. doi: 10.1038/s41440-018-0041-5. Epub 2018 Apr 13.

PMID:
29654295
13.

Response: Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlled-release carbamazepine in noninferiority epilepsy monotherapy trials: How much "fair" is "fair".

Trinka E, Rocha JF, Soares-da-Silva P.

Epilepsia. 2018 Apr;59(4):900-901. doi: 10.1111/epi.14062. No abstract available.

PMID:
29604066
14.

Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs.

Mintzer S, Wechsler RT, Rogin JB, Gidal BE, Schwab M, Ben-Menachem E, Carreño M, da Silva PS, Moreira J, Li Y, Blum D, Grinnell T.

Epilepsy Res. 2018 Mar;141:83-89. doi: 10.1016/j.eplepsyres.2018.02.001. Epub 2018 Feb 9.

15.

In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.

Bicker J, Alves G, Fortuna A, Soares-da-Silva P, Falcão A.

Eur J Pharm Sci. 2018 May 30;117:35-40. doi: 10.1016/j.ejps.2018.02.006. Epub 2018 Feb 8.

PMID:
29428540
16.

Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.

Trinka E, Ben-Menachem E, Kowacs PA, Elger C, Keller B, Löffler K, Rocha JF, Soares-da-Silva P.

Epilepsia. 2018 Feb;59(2):479-491. doi: 10.1111/epi.13993. Epub 2018 Jan 25.

17.

Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.

Krauss G, Biton V, Harvey JH, Elger C, Trinka E, Soares da Silva P, Gama H, Cheng H, Grinnell T, Blum D.

Epilepsy Res. 2018 Jan;139:1-8. doi: 10.1016/j.eplepsyres.2017.10.021. Epub 2017 Nov 4.

18.

Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.

Elger C, Koepp M, Trinka E, Villanueva V, Chaves J, Ben-Menachen E, Kowacs PA, Gil-Nagel A, Moreira J, Gama H, Rocha JF, Soares-da-Silva P.

CNS Neurosci Ther. 2017 Dec;23(12):961-972. doi: 10.1111/cns.12765. Epub 2017 Oct 13.

19.

Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors.

Bicker J, Fortuna A, Alves G, Soares-da-Silva P, Falcão A.

Drug Metab Dispos. 2017 Dec;45(12):1282-1291. doi: 10.1124/dmd.117.077883. Epub 2017 Sep 15.

PMID:
28916530
20.

The effect of PRR ligands on the membrane potential of intestinal epithelial cells.

Magalhães D, Soares-da-Silva P, Magro F.

Pharmacol Rep. 2017 Oct;69(5):978-984. doi: 10.1016/j.pharep.2017.04.010. Epub 2017 Apr 23.

PMID:
28837901

Supplemental Content

Loading ...
Support Center